Hyloris Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.03.24	Hyloris Reports Full Year Results for 2023 & Provides Business Outlook (GlobeNewswire)
14.03.24	Communication at the request of the FSMA on the transactions with Qliniq (GlobeNewswire)
08.03.24	Hyloris to Report 2023 Full-Year Results on 14 March 2024 (GlobeNewswire)
27.02.24	Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada (GlobeNewswire)
14.02.24	Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures (GlobeNewswire)
30.01.24	Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) (GlobeNewswire)
18.01.24	Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS) (GlobeNewswire)
16.01.24	Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) (GlobeNewswire)
26.12.23	Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029) (GlobeNewswire)
21.12.23	Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome (GlobeNewswire)
04.12.23	Hyloris announces US FDA approval for Podofilox Gel (GlobeNewswire)
24.10.23	Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada (GlobeNewswire)
18.10.23	Hyloris announces U.S. FDA Approval of Maxigesic® IV (GlobeNewswire)
06.09.23	Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook (GlobeNewswire)
22.06.23	Hyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM) (GlobeNewswire)
13.06.23	Hyloris shareholders approve all resolutions at the Annual General Meeting (GlobeNewswire)
08.06.23	Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region (GlobeNewswire)
02.05.23	Hyloris announces potential registration date for Maxigesic® IV in the US (GlobeNewswire)
28.04.23	Hyloris releases Annual Report 2022, including ESG objectives (GlobeNewswire)
18.04.23	Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA (GlobeNewswire)
15.03.23	Hyloris reports full year results for 2022 & provides business outlook (GlobeNewswire)
01.04.22	Hyloris Successfully Raises EUR 15.0 Million in an Equity Offering by Means of A Private Placement Via an Accelerated Bookbuild Offering (GlobeNewswire)
31.03.22	Hyloris Launches Equity Offering by Means of a Private Placement Via an Accelerated Bookbuild Offering (GlobeNewswire)
16.03.22	Correcting -- Hyloris reports results for the full year 2021 (GlobeNewswire)
16.03.22	Hyloris reports results for the full year 2021 (GlobeNewswire)
04.08.21	Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead (GlobeNewswire)
27.07.21	Hyloris to Report 2021 Half-Year Results on 4 August 2021 (GlobeNewswire)
08.07.21	Hyloris Announces Launch of Maxigesic® IV, a Novel Non-Opioid Pain Treatment, in Key European Markets (GlobeNewswire)
24.06.21	Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group (GlobeNewswire)
28.04.21	Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Hyloris Pharmaceuticals SA Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten